RECURRENT TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA
Clinical trials for RECURRENT TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for RECURRENT TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Double-Punch trial aims to tame aggressive blood cancer
Disease control Recruiting nowThis study is testing whether combining two targeted cancer drugs is safe and effective for patients with an aggressive type of lymphoma that has come back or stopped responding to other treatments. The two drugs work together: one delivers a toxin directly to cancer cells, while…
Matched conditions: RECURRENT TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New Triple-Target immune therapy enters human trials for aggressive blood cancers
Disease control Recruiting nowThis early-stage trial is testing the safety and best dose of a new type of CAR-T cell therapy designed to attack three different proteins (CD19, CD20, and CD22) found on cancer cells. It is for adults with certain aggressive blood cancers like non-Hodgkin lymphoma, acute lymphob…
Matched conditions: RECURRENT TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
Double-Punch combo trial aims to tame aggressive cancer
Disease control Recruiting nowThis study is testing a two-part treatment for Richter's syndrome, an aggressive cancer that develops from a slower-growing blood cancer. It combines a daily pill (zanubrutinib) with a one-time infusion of specially modified immune cells (CAR-T therapy) to attack the cancer. The …
Matched conditions: RECURRENT TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: Aseel Alsouqi • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
Triple-Threat attack on rare, deadly blood cancer
Disease control Recruiting nowThis study is testing a new combination of three cancer drugs for patients with Richter's transformation, a rare and aggressive form of blood cancer that develops from chronic lymphocytic leukemia (CLL). The treatment combines a personalized cell therapy (made from the patient's …
Matched conditions: RECURRENT TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New engineered immune cell therapy enters first human trials for aggressive blood cancers
Disease control Recruiting nowThis is an early-stage study testing a new type of personalized cell therapy called MC10029 for adults with B-cell blood cancers that have come back or stopped responding to standard treatments. Researchers will first find the safest dose and then see if the therapy can shrink tu…
Matched conditions: RECURRENT TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 27, 2026 12:37 UTC
-
First-in-Human trial tests new drug duo for aggressive blood cancer
Disease control Recruiting nowThis early-stage study is testing a new combination of two drugs, zanubrutinib and odronextamab, for patients with Richter's transformation, a fast-growing lymphoma. The main goal is to find a safe dose and understand the side effects. Researchers will also check if the treatment…
Matched conditions: RECURRENT TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC